Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Eli Lilly and Company    LLY

ELI LILLY AND COMPANY

(LLY)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Eli Lilly, Innovent : Tyvyt Combo Meets Main Endpoint in Phase 3 Study

share with twitter share with LinkedIn share with facebook
share via e-mail
01/13/2020 | 10:00am EST

By Colin Kellaher

Eli Lilly & Co. (LLY) and Innovent Biologics Monday said a phase 3 study in China of Tyvyt in combination with Alimta and platinum met its primary endpoint of progression-free survival in a form of lung cancer.

The companies said the combination showed a statistically significant improvement in progression-free survival compared with placebo in first-line advanced or recurrent nonsquamous non-small cell lung cancer, without sensitive EGFR mutation or ALK rearrangement.

The safety profile of Tyvyt, which Innovent and Eli Lilly are jointly developing in China, was consistent with previous studies, and no new safety signals were identified, the companies said.

Eli Lilly and Innovent said they plan to initiate talks for registration with China's National Medical Products Administration in the near future.

Write to Colin Kellaher at colin.kellaher@wsj.com

Stocks mentioned in the article
ChangeLast1st jan.
ELI LILLY AND COMPANY 0.03% 142.04 Delayed Quote.8.07%
INNOVENT BIOLOGICS INC -1.48% 33.25 End-of-day quote.-3.06%
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on ELI LILLY AND COMPANY
02/21ELI LILLY AND : Trulicity® (dulaglutide) is the first and only type 2 diabetes m..
PR
02/21ELI LILLY AND : Lilly to Participate in Cowen Health Care Conference
PR
02/21ELI LILLY AND : Lilly To Participate in SVB Leerink Global Healthcare Conference
PR
02/21Pharmaceutical companies develop system to better track counterfeit drugs
RE
02/20EXCLUSIVE : Canadian regulator considers changes to new drug pricing plan
RE
02/19ELI LILLY AND : & CO Management's Discussion and Analysis of Results of Operatio..
AQ
02/19ELI LILLY AND : Backed Terns Reports Positive Phase 1 Results for TERN-101 in NA..
DJ
02/13ELI LILLY AND COMPANY : Ex-dividend day for
FA
02/11ELI LILLY AND : Lilly Announces Topline Results for Solanezumab from the Dominan..
AQ
02/11EAGLE PHARMACEUTICALS : Receives final fda approval for pemfexy
AQ
More news
Financials (USD)
Sales 2020 23 964 M
EBIT 2020 7 401 M
Net income 2020 5 485 M
Debt 2020 10 799 M
Yield 2020 2,05%
P/E ratio 2020 22,5x
P/E ratio 2021 17,7x
EV / Sales2020 5,82x
EV / Sales2021 5,44x
Capitalization 129 B
Chart ELI LILLY AND COMPANY
Duration : Period :
Eli Lilly and Company Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ELI LILLY AND COMPANY
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 17
Average target price 146,80  $
Last Close Price 142,04  $
Spread / Highest target 18,3%
Spread / Average Target 3,35%
Spread / Lowest Target -20,4%
EPS Revisions
Managers
NameTitle
David A. Ricks Chairman, President & Chief Executive Officer
Myles Oneill Senior VP & President-Manufacturing Operations
Joshua L. Smiley Chief Financial Officer & Senior Vice President
Timothy J. Garnett Chief Medical Officer & VP-Global Medical
Aarti S. Shah Chief Information Officer & SVP-IT
Sector and Competitors
1st jan.Capitalization (M$)
ELI LILLY AND COMPANY8.07%128 743
JOHNSON & JOHNSON1.71%395 024
ROCHE HOLDING AG10.08%300 195
NOVARTIS2.89%218 568
MERCK AND COMPANY-9.47%209 636
PFIZER-8.50%197 679